1 suspended, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Suspended 1, Terminated 1 |
| Phase 2 | 1 | Suspended 1 |
Follow Vevoctadekin: new trials by email Literature Review of Vevoctadekin trials Research Report on Vevoctadekin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Terminated | University of Washington | 1 | 2024-12-18 | 2025-07-29 |
Lymphoma, Large B-Cell, Diffuse (1) · Multiple Myeloma (1)
Fred Hutchinson Cancer Center (1) · University of Washington (1)
United States (2)
Alexandre V. Hirayama, MD (1) · Rahul Banerjee, MD (1)